Umbralisib

Time-limited dual B-cell receptor inhibitor therapy with acalabrutinib, umbralisib and ublituximab showed potential in treatment-naive and relapsed/refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

In the latest installment of Residency to Retirement, experts discussed how physicians can safeguard their assets from inflation. It was the top story in hematology/oncology last week.

The FDA has withdrawn approval of umbralisib for marginal zone lymphoma and follicular lymphoma due to safety concerns, according to an updated drug safety communication.

The FDA Oncologic Drugs Advisory Committee voted Thursday in favor of randomized data to support future approvals of phosphatidylinositol-3-kinase inhibitors, which are being developed for patients with hematologic malignancies.

The FDA is investigating a possible increased mortality risk with umbralisib, approved in the United States for treatment of two types of lymphoma.

The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with chronic lymphocytic leukemia and Bruton tyrosine kinase inhibitor risk factors.

The FDA granted accelerated approval to umbralisib for two types of relapsed or refractory lymphoma.

The combination of umbralisib and ublituximab significantly improved PFS compared with chemoimmunotherapy for patients with chronic lymphocytic leukemia, according to study results presented at the virtual ASH Annual Meeting and Exposition.

The FDA granted fast track designation to the combination of ublituximab and umbralisib for the treatment of adults with chronic lymphocytic leukemia, according to a press release from the drugs’ manufacturer.

The FDA granted priority review to umbralisib for patients with previously treated marginal zone lymphoma, according to the agent’s manufacturer.